Search Results

RION, a clinical-stage regenerative medicine company at the forefront of exosome therapeutics, announced today the first subject was dosed in the Phase 2 clinical trial with its novel product, known as Purified Exosome Product™ (PEP™).

May 7, 2024

·

5 min read

BioMidwest

Rion to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Rion today announced Dr. Atta Behfar, Co-Founder, will present at the 42nd Annual JP Morgan Healthcare Conference on Wednesday, January 10, 2024, at 02:00 PM.

January 2, 2024

·

1 min read

Drug Development

RION Announces Initiation of Phase 2A Clinical Study for Purified Exosome Product™ (PEP™) in Diabetic Foot Ulcers

RION’s Phase 2A clinical trial focuses on evaluating the safety and efficacy of Platelet Exosome Product™ (PEP™) combined with TISSEEL fibrin sealant for treating Diabetic Foot Ulcers (DFU).

January 30, 2024

·

6 min read

Business

RION Announces the Advisory Appointments of John Ballantyne, Ph.D., to Chair of the Rion Scientific Advisory Board and Andrew D. Badley, M.D., to Chair of the Rion Medical Advisory Board

RION, a clinical-stage regenerative medicine company with breakthrough platform technology leveraging platelet-derived exosomes, announces the appointment of Dr. Ballantyne as Chair of the company’s Scientific Advisory Board and Dr. Andrew D. Badley as Chair of the Rion Medical Advisory Board.

January 25, 2023

·

4 min read

BioMidwest

RION, Mayo Clinic, and the U.S. Army Medical Research Institute for Chemical Defense Receive $2.4M Department of Defense Award to Advance Exosome-Based Research in Pulmonary Therapeutics

RION, a leading clinical-stage regenerative medicine company, announced that it will collaborate with Mayo Clinic and the U.S. Army Medical Research Institute for Chemical Defense on a $2.4M grant awarded from the Department of Defense.

November 20, 2023

·

3 min read

Business

RION Appoints Alisa Lask as Chief Commercial Officer

RION, a biotechnology company headquartered in Rochester, Minnesota pioneering new innovations in exosomes for therapeutic and aesthetic indications, today announced the appointment of Alisa Lask as Chief Commercial Officer.

January 14, 2022

·

2 min read